BioPharma Dive
Section 232 national security levies won’t apply to a wide array of drugs, meaning the overall threat to the sector should be low, according to one analyst.
BioPharma Dive
Section 232 national security levies won't apply to a wide array of drugs, meaning the overall threat to the sector should be low, according to one analyst.
BioPharma Dive
Section 232 national security levies won’t apply to a wide array of drugs, meaning the overall threat to the sector should be low, according to one analyst.